Track market-moving stories before they get noisy

SEOUL, South Korea--(BUSINESS WIRE)--Ralph Lauren (NYSE:RL) today announced a partnership with the Korea National Cancer Center Foundation to establish The Ralph Lauren Center for Patient and Family Recovery at the National Cancer Center of Korea (NCC) in Goyang, South Korea, marking the first Ralph Lauren cancer center in Asia. Building on Ralph Lauren's longstanding support for cancer prevention and treatment efforts, the new center represents the next chapter in its commitment to expanding a.

Guidewire Software, Inc. (NYSE:GWRE) had one of the ugliest earnings reactions in software this quarter. The Guidewire stock drop reached as much as 20.8% during the day on Friday, September 5, 2026. Shares hit a low of $157.05 and later settled in the $160-$166 range.

That’s well below Thursday’s closing price of $202.86. As a result, the sell-off wiped out more than $2 billion in market value in a single session.

Yet the company topped Street estimates on both revenue and profit. Instead, investors zeroed in on a soft first-quarter guide. They also spotted early signs that the ARR growth story is cooling. This Guidewire stock drop fits a pattern seen across software earnings this season.

The Numbers Behind The Guidewire Stock DropGuidewire’s fiscal Q4 2026 results were announced on Thursday evening. Overall, they cleared the bar comfortably:

Adjusted EPS of $0.99 vs. the $0.93 consensusRevenue of $411.1 million vs. ~$402.7 million estimate, up 23% year-over-yearARR of $1.242 billion, up 19% year-over-year and above guidanceCloud ARR up 35% year-over-year, now 84% of total ARROperating income of $340 million, up 63% year-over-yearGross ARR attrition below 1.5% company-wideCEO Mike Rosenbaum made an optimistic statement and said that the transition to cloud technologies is proceeding in accordance with expectations. In particular, he noted an increase in margins and cash flow. He also mentioned PricingCenter’s new deal with Nationwide.

So Why Did The Guidewire Stock Drop Happen?The last quarter looked great on paper but investors were already thinking ahead to what comes next for Guidewire, and that’s where we have the worry.

Light Q1 FY27 revenue guide: According to Guidewire’s forecast, revenue in Q1 2027 amounted to 372-378 million dollars. This is ~3.3% lower than analysts’ forecasts. Consequently, this led to an immediate decrease in sales after business hours. ARR growth is decelerating: Full-year FY27 ARR guidance implies growth of ~18%. That’s down from 19% in FY26. According to management, part of this reflects normalizing attrition rates. License revenue headwind: Guidewire flagged a $46 million license revenue decline for FY27. This shows the ongoing shift toward subscription-based cloud contracts. Valuation And Macro PressureTwo more factors made things even worse:

Valuation left no room for error and heading into earnings, GWRE traded above a 120x trailing P/E. Therefore, a "beat and maintain" quarter wasn’t enough as Wall Street wanted "beat and raise". Macro crosswinds added pressure and a strong U.S. jobs report reignited debate over Fed rate policy. This weighed on high-multiple software names broadly, so there was no market cushion left for GWRE’s stumble. Wall Street’s Reaction Was Mixed, Not BearishNotably, analysts didn’t abandon the stock. and most kept bullish ratings. Still, they changed price targets to reflect the reset:

Oppenheimer kept "Outperform" and raised its target to $210 DA Davidson reiterated "Buy" with a $222 target Baird kept "Outperform" with a $235 target Goldman Sachs held "Buy" while cutting its target from $255 to $225 Overall, the Street consensus is a "Moderate Buy." In fact, average targets still imply solid upside from Friday’s price.
So what’s the takeaway? The deceleration looks real, but modest. Meanwhile, over half of next year’s net-new ARR is already under contract and also, record-low attrition suggests the core franchise stays durable.

The Bigger PictureGWRE now trades over 40% below its 52-week high of $272.60. Still, it remains well above its 52-week low of $102.30. The stock has logged nearly 40 moves greater than 5% this past year. Even so, Friday’s drop stands out. Ultimately, this Guidewire stock drop shows that “very good” guidance isn’t good enough for a stock priced for perfection. So is this a healthy reset? Or is it the first crack in an overheated growth story? That’s the question investors now face.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články  

09.09.2026 12:28

Rozvíjející se trhy zažívají mimořádně silné období díky globálním investicím do AI infrastruktury. Analytici letos zvýšili odhady zisků společností zahrnutých do indexu MSCI Emerging Markets o rekordních 65 %, což představuje nejrychlejší tempo růstu v historii sledování tohoto ukazatele.

Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.

V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.

Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více

Tagy: emerging markets, MSCI, Výhled, Zisky, rozvíjející se ekonomiky
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

09.09.2026 12:28Rozvíjející se trhy těží z AI boomu. Odhady zisků v indexu MSCI EM rostou nejrychleji v historii   11:44ČEZ získal povolení k použití jaderného paliva od Westinghouse v Temelíně 11:14Ropa za 100 a strach z inflace drží sentiment dole   10:37Trénoval modely pro OpenAI i Anthropic, teď opouští obor a varuje před podceňováním rizik 9:23Bessent vyhlašuje válku spekulantům, chce zastavit útoky na jen 8:58Rozbřesk: Minimální mzda výrazně vzroste, jaké budou dopady do české ekonomiky? 8:37USA přitvrzují v obchodní válce s Kanadou, ropa je už na 99 dolarech, Evropa otevře poklesem   8:35EU a Kanada chystají strategické partnerství. Chtějí posílit obchod, obranu i nezávislost na velmocích 6:03ASML dostalo od klíčových zákazníků zelenou pro novou generaci litografických strojů 08.09.2026 22:01Akcie i dluhopisy oslabily, růst ropy zvýšil obavy z dalšího růstu sazeb   17:06Do popředí vystupuje paradox na zlatu 15:43Starteepo vyzvala Xerox k odemčení hodnoty finanční divize 13:29Tesla rozjíždí Cybercabs, přichází čínská automobilová expanze ve Spojených státech 11:57Po klidném létě může přijít bouřlivý podzim. Trhy čeká test inflace, dluhu i geopolitiky   11:56Volkswagen zvažuje prodej Ducati. Ikonická motocyklová značka může pomoci financovat restrukturalizaci 11:35Výnosy dluhopisů stoupají, akcie jsou pod tlakem. Není to jen o ropě a obavách z inflace   10:53Evropský AI šampion Mistral získal rekordní finance a míří mezi technologickou elitu 10:15Neúspěchy farmaceutických gigantů: Novartis zklamal v klíčové zkoušce, Novo Nordisk ruší studie 8:54Jen sílí, měď láme rekordy a ropa míří ke 100 dolarům   8:53Rozbřesk: Průmysl jede dál, noví tahouni na obzoru?
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

ČasUdálost PL - Jednání NBP, základní sazba 3:30Čína - CPI, y/y

-

Bringing biocompatible, clinically effective skincare to communities across Mexico and Canada

LOS ANGELES--(BUSINESS WIRE)--Today, Naturium, a brand from e.l.f. Beauty (NYSE: ELF), announced its expansion with Sephora across Canada and Mexico, bringing its biocompatible, clinically effective skincare to new consumers across North America. Delivering affordable luxury for head-to-toe skincare, the brand makes its official debut in Mexico exclusively in Sephora Mexico stores and on Sephora.com.mx, while broadening its Canadian retail footprint online and in Sephora Canada stores nationwide.

Since its launch in 2019, Naturium has built a loyal, community-driven following based on a simple idea: effective skincare should be easy to understand and incorporate into everyday life. The Sephora expansion marks the next step in the brand’s continued growth, bringing its mission of ‘skin love for everyone’ to more consumers across North America. With the addition of these two markets, Naturium is now available in six regions globally.

“To see Naturium continue to grow and reach new markets is incredibly meaningful to us. We have been working to expand Naturium’s retail presence internationally and getting the best of Naturium into more hands,” said Suzanne Pengelly, President of Naturium. “We’ve built Naturium around products people genuinely love making part of their everyday routines, and we can’t wait for even more consumers to discover them.”

“We’re very happy to welcome Naturium to Sephora Mexico and add to our portfolio a brand that combines innovation, clinical efficacy, and an accessible approach to skincare,” said Mauricio Padilla, CEO of Sephora Mexico. “We’re confident its proposition will strongly resonate with our clients, and we’re excited to be its exclusive retail destination in Mexico.”

At Sephora Canada and Sephora Mexico, consumers can find an assortment of Naturium’s bestselling skincare and body care formulas, including:

Glow Getter Multi-Oil Hydrating Body Wash – Best-selling vanilla coconut body wash that delivers a multi-oil glow from head to toe. Glow Getter Multi-Oil Body Butter – Luxurious, vanilla coconut, fast absorbing body butter includes 81% multi-oil complex for glowing, replenished and firmer-looking skin. Multi-Peptide Moisturizer – Clinically-proven moisturizer that improves wrinkles & hydration in 100% of consumers and firmness in 97% of consumers. Vitamin C Complex Serum – Gold stabilized Vitamin C delivered in a biocompatible, ph-balance that is suitable for all skin types. To celebrate its launch in Sephora Canada, Naturium is rolling out a brand campaign across Canada featuring its Canadian community and their love of skincare, including partnerships with creators that are long-time brand fans, and have championed Naturium for years. The brand will also host an experiential activation on September 12 in Toronto at The Well, where guests can enjoy a special photobooth experience, product education, customized skincare routines, and take home some of the brand's most loved products.

Beginning September 9, Naturium will be available online at sephora.com/ca/en/ and in Sephora Canada stores nationwide. In Mexico, Naturium will be available exclusively at Sephora Mexico stores and on Sephora.com.mx.

About Naturium
Founded in 2019, Naturium brings the science of consistent skincare to every one, every where, every day. The brand's biocompatible and dermatologist-tested formulas work with individual skin's biology from head to toe, blending natural botanicals with potent actives for clinically effective results at an accessible price point. Naturium has pioneered facial and body care innovations. Naturium is clean, vegan, paraben-free, and double-certified by Leaping Bunny and PETA as cruelty-free. Acquired by e.l.f. Beauty (NYSE: ELF) in 2023, the brand is available at naturium.com and both in-store and online at Target and Ulta in the U.S.

About Sephora
Sephora is the world’s leading global prestige beauty retail brand. With 55,000 passionate employees operating in 37 markets, Sephora connects customers and beauty brands within the world’s most trusted and dynamic beauty community. We serve a highly engaged community of hundreds of millions of beauty followers across our global omnichannel network of more than 3,400 stores and iconic flagships, and our e-commerce and digital platforms, offering personalized and immersive seamless experiences across every touchpoint. With our curation of more than 500 brands and our own label, Sephora Collection, we offer the most unique and diverse range of prestige beauty products, tailored to our customers’ needs from fragrance to make-up, haircare, skincare and beyond, as we constantly reimagine the world of prestige beauty. Since SEPHORA’s inception in 1969 in Limoges, France, and as part of the LVMH Group since 1997, the brand has been disrupting the prestige beauty retail industry. Today, they continue to break with convention to drive their mission: champion a world of inspiration and inclusion where everyone can celebrate their beauty. For more information, visit www.sephora.com.

More News From Naturium

Back to Newsroom

Partnership Expands Access to the BioCode® MDx-3000 System for Hospitals and Reference Laboratories

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode today announced a distribution agreement with Henry Schein, a leading provider of healthcare products and services, to expand the availability of its BioCode® MDx-3000 System and comprehensive molecular diagnostics menu.

"Helping broaden access to advanced molecular diagnostic capabilities"

Share The BioCode® MDx-3000 is an automated, high-throughput multiplex molecular diagnostic platform designed to support high-complexity clinical laboratories. Its testing menu includes upper respiratory and gastrointestinal infection panels, with a customizable menu option, enabling laboratories to deliver accurate, cost-effective, and efficient molecular diagnostic testing.

Through this agreement, Henry Schein will distribute the MDx-3000 System and its associated assays to hospitals, health systems, and reference laboratories nationwide, helping broaden access to advanced molecular diagnostic capabilities.

"Applied BioCode is excited to partner with Henry Schein as we continue expanding our presence in hospitals and reference laboratories across the United States," said Jim Leigh, Sr. Vice President of Sales. "Henry Schein's extensive laboratory distribution network makes them an ideal partner to help bring our innovative molecular diagnostic solutions to more clinical laboratories."

Applied BioCode remains committed to advancing molecular diagnostics through innovative technologies that improve laboratory workflows and deliver accurate, reliable, and actionable results for healthcare providers and patients.

About Applied BioCode

Applied BioCode is a leading provider of molecular diagnostic solutions, focused on developing innovative technologies that empower clinical laboratories, improve operational efficiency, and enhance patient care.

To learn more about Applied BioCode's molecular diagnostic solutions, visit:

https://www.apbiocode.com/products/.

Investors interested in Financial - Investment Management stocks are likely familiar with Patria Investments (PAX - Free Report) and KKR & Co. Inc. (KKR - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Patria Investments and KKR & Co. Inc. are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that PAX likely has seen a stronger improvement to its earnings outlook than KKR has recently. However, value investors will care about much more than just this.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

PAX currently has a forward P/E ratio of 8.10, while KKR has a forward P/E of 16.49. We also note that PAX has a PEG ratio of 0.76. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. KKR currently has a PEG ratio of 0.88.

Another notable valuation metric for PAX is its P/B ratio of 1.19. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, KKR has a P/B of 1.29.

Based on these metrics and many more, PAX holds a Value grade of A, while KKR has a Value grade of D.

PAX has seen stronger estimate revision activity and sports more attractive valuation metrics than KKR, so it seems like value investors will conclude that PAX is the superior option right now.

Key Takeaways NuFormer is expanding across credit, customer service and growth campaigns at NU.NU's $39.4 billion credit portfolio grew 37%, while risk-adjusted NIM rose to 12.4%.NuFormer now runs faster and cheaper, with AI agents handling over 60% of Brazil support chats. Nu Holdings Ltd. (NU - Free Report) is putting artificial intelligence deeper into its operating model, with NuFormer central to underwriting, customer service and growth. The company said the model draws on more than a decade of transaction history across over 100 million customers in Brazil, Mexico and Colombia, giving it a large base of financial behavior data.

NuFormer has become faster and cheaper to run. Its latest generation quadrupled its context length, training speed and inference speed while lowering production costs. The model is used for credit cards in Brazil and Mexico and unsecured lending in Brazil, while SME credit cards and Colombian cards are being tested.

The push matters because credit remains a major earnings driver. NU ended the second quarter of 2026 with a $39.4 billion credit portfolio, up 37% year over year. Risk-adjusted net interest margin rose to 12.4% from 9.5% in the first quarter, helped by stronger credit income and a lower cost of credit.

AI is also moving beyond underwriting. Generative AI agents now handle more than 60% of customer support conversations in Brazil, with ratings at or above human levels. NuFormer is also being used to target growth campaigns, with more than 100 campaigns already run using the platform.

The financial backdrop gives NU room to invest. Second-quarter 2026 gross revenues reached $5.9 billion, up 39% year over year, while net income hit $1.1 billion. The company served 139 million customers, ARPAC reached $17 and the efficiency ratio stood at 19.5%, showing that AI investment is being layered onto a scaled platform.

How Are Itau Unibanco & MercadoLibre Compete?Itau Unibanco (ITUB - Free Report) , a major Brazilian banking rival to Nu Holdings, is embedding generative AI across customer service, business banking and payments. In June 2026, Itau Unibanco partnered with Google to expand Gemini access and AI training for SMEs. By late July 2026, its ia.i assistant was already available to approximately 300,000 Superapp users.

MercadoLibre (MELI - Free Report) , via its Mercado Pago platform, competes with Nu Holdings across Latin American payments, credit and digital financial services. The company uses AI and machine learning in credit scoring, customer service, advertising and marketplace search. In second-quarter 2026, MELI completed the rollout of an AI powered search architecture across its five largest sites. In second-quarter 2026, Mercado Pago reached 88 million monthly active users.

NU’s Price Performance, Valuation and EstimatesShares of NU have gained 29.4% in the past three months, outperforming the broader industry and the S&P 500 Index.

Image Source: Zacks Investment Research

From a valuation standpoint, NU trades at a forward price-to-earnings ratio of 14.38X, well above the industry’s 11.55X. It carries a Value Score D.

Image Source: Zacks Investment Research

NU’s estimates have increased 3 cents over the past month. The Zacks Consensus Estimate for full-year 2026 EPS is pegged at 86 cents.

Image Source: Zacks Investment Research

NU stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DES MOINES, Iowa, Sept. 8, 2026 /PRNewswire/ -- F&G Annuities & Life, Inc. (NYSE: FG) (F&G) today announced that Conor Murphy, CEO & President, and Michael Bailey, EVP, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Financial Services Conference on Monday, September 14, 2026 at 9:45 am Eastern Time.

1.75K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MPLX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

EU regulators are preparing to warn Hong Kong-listed mining and metals company MMG (1208.HK) ​over its plan to buy Anglo American's (AAL.L) Brazilian nickel business ‌because of competition concerns, three people familiar with the matter said.

The step reflects mounting European Union concern about the bloc's reliance on China for critical ​minerals vital to defence, technology and renewable energy and Beijing's ​use of export control measures on critical mineral supplies.

The ⁠European Commission, which acts as the EU competition enforcer, is ​preparing to send out this month what is known as a ​statement of objections or a charge sheet, setting out the concerns that will need to be addressed for the deal to be cleared, the people said. ​They spoke on condition of anonymity because the matter is ​not yet public.

MMG could stave off the charge sheet by offering remedies, but ‌this ⁠is regarded as unlikely, one of the people said.

The EU antitrust watchdog and MMG declined to comment. Anglo American reiterated comments issued two weeks ago.

"The evidence we've provided demonstrates that this transaction poses ​no competition concerns ​to the EU ⁠market and should be approved unconditionally," it said in a statement to Reuters.

"Over the past year, ​the market has benefited from a significant structural expansion ​of ⁠FeNi supply from a number of producers, whilst European customers have shown how readily they can switch between their various suppliers," it said.

The ⁠Commission ​in November said the deal could enable MMG ​to divert ferronickel from Europe and undermine the competitiveness of European stainless steel production.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of the November 2, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Should You Join The Hims Class Action Lawsuit:

Do you, or did you, own shares of Hims, Inc. (NYSE: HIMS)?Did you purchase your shares between August 4, 2025 and July 29, 2026, inclusive?Did you lose money in your investment in Hims, Inc.?
What To Do Next:

Investors are encouraged to act promptly and submit a form at Hims & Hers Health, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

If you wish to serve as lead plaintiff for the Class, you must file papers by November 2, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About The Lawsuit:

A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the securities of Hims between August 4, 2025 and July 29, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.

The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Hims securities traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.

About Bernstein Liebhard:

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: August 4, 2025 to July 29, 2026

DEADLINE: November 2, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Hims & Hers provided customer health data to third-party advertising platforms. The Company’s treatment practices were likely to result in heightened regulatory scrutiny. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Hims & Hers, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

 Schall, Brown & Schwartz LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - September 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" or the "Company") (NASDAQ: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, during market hours, the Federal Trade Commission announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." On this news, Hims's stock price fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hims class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hims Securities Class Action Lawsuit:

What is the Hims securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Hims & Hers Health, Inc. (NASDAQ: HIMS) made materially false and misleading statements to investors during the Class Period. The complaint alleges that the Company shared consumers' sensitive health information with third-party advertising platforms despite representing that its services maintain consumer privacy, and that the Company allegedly charged consumers for prescriptions almost immediately after intake form submission while telling consumers they would first be able to consult with a medical provider. The lawsuit further alleges that this conduct subjected Hims to regulatory scrutiny and made the Company reasonably likely to incur fees and penalties. On July 29, 2026, the Federal Trade Commission announced it had filed a lawsuit against Hims alleging these practices, and on that news Hims's stock price allegedly fell $4.32, or approximately 14.73%, to close at $25.00 per share on unusually heavy trading volume. As a result of the foregoing, the complaint alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NASDAQ: HIMS) on the NASDAQ exchange between August 4, 2025 and July 29, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate in any potential recovery is not limited to investors who seek appointment as lead plaintiff; any investor who purchased Hims securities during the Class Period may be a class member. Eligible investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Investors with questions about their eligibility may wish to consult with counsel to better understand their rights and options in connection with this litigation.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Any investor who purchased Hims securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, provided that motion is filed no later than November 2, 2026. Courts typically appoint the investor or group of investors with the largest financial interest in the litigation who also satisfy the requirements of Federal Rule of Civil Procedure 23 as lead plaintiff. Importantly, an investor need not seek appointment as lead plaintiff in order to participate in or share in any recovery that may result from the litigation. Investors who do not seek lead plaintiff status retain the right to remain members of the class and benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hims securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313376

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

San Francisco, California--(Newsfile Corp. - September 8, 2026) - Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct.

Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 4, 2025 - July 29, 2026
Lead Plaintiff Deadline: Nov. 2, 2026
Visit Hims Investigation Page: www.hbsslaw.com/hims
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895

Hims & Hers Health ($HIMS) Securities Class Action

The lawsuit is focused on the propriety of Hims' repeated assurances that "[w]e have developed and maintain policies and procedures with respect to health information and personal information that we use or disclose in connection with our operations, including the adoption of administrative, physical, and technical safeguards to protect such information."

The complaint alleges that Hims: (1) shared consumers' health information with third-party advertising platforms; (2) charges consumers for prescriptions almost immediately after they submit intake forms, despite telling them that they will be able to consult with a medical provider to find a treatment that is "right for them[;]" and (3) as a result, would be subject to heightened regulatory scrutiny and likely to incur fees and penalties.

What Drove the $HIMS July 29, 2026 Stock Crash? The FTC and State Lawsuit Breakdown

The securities class action cites the July 29, 2026 federal complaint filed against Hims by the FTC-alongside co-plaintiffs the State of Utah and the County of Los Angeles (representing California).

After an extensive investigation by the Commission, it contends that Hims engaged in:

Deceptive Health Data Sharing: Despite extensive marketing campaigns emphasizing strict privacy, discreet telehealth consultations, and data protection, the complaint alleges that Hims surreptitiously shared sensitive user medical conditions and personal health data with third-party advertising giants, including Meta Platforms (Facebook) and Snap, via embedded tracking pixels and customer list matching. Subscription Billing & Cancellation Barriers (ROSCA Violations): The lawsuit accuses Hims of violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscription models without informed consent. According to regulators, consumers were billed for prescriptions almost immediately upon completing an intake form-long before receiving any consultation with a medical provider-while facing dark patterns and hidden cancellation options designed to prevent subscription termination.The market swiftly reacted, sending the price of Hims shares down $4.32 (-14.7%) and erasing over $970 million from the company's market capitalization in a single day.

"We're focused on whether Hims may have intentionally misled investors about its business practices, including the adequacy of its internal controls, and financial ramifications of the alleged misconduct," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in HIMS and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding HIMS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313516

Source: Hagens Berman Sobol Shapiro LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.

SO WHAT: If you purchased Hims securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Hims shared consumers' health information with third-party advertising platforms; (2) Hims charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected Hims to regulatory scrutiny; (4) as a result of the foregoing, Hims was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, defendants' positive statements about Hims' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hims class action, go to https://rosenlegal.com/cases/hims-hers-health-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313572

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Restaurant Brands International Inc. (TSE:QSR – Get Free Report) (NYSE:QSR) Director Vicente Tome sold 2,258 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of C$112.93, for a total transaction of C$254,995.94. Following the completion of the transaction, the director owned 13,264 shares in the company, valued at approximately C$1,497,903.52. The trade was a 14.55% decrease in their ownership of the stock.

Shares of QSR stock opened at C$110.91 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.01 and a debt-to-equity ratio of 406.52. The firm has a market cap of C$38.68 billion, a P/E ratio of 29.89, a PEG ratio of 2.22 and a beta of 0.31. The company has a 50 day moving average of C$106.14 and a 200-day moving average of C$104.23. Restaurant Brands International Inc. has a 12-month low of C$84.78 and a 12-month high of C$113.10.

Restaurant Brands International Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Tuesday, July 7th were paid a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Tuesday, June 23rd. Restaurant Brands International’s payout ratio is currently 68.46%.

About Restaurant Brands International (Get Free Report) Restaurant Brands International is one of the largest restaurant companies in the world, with more than $35 billion in 2021 systemwide sales across a footprint that spans more than 28,000 restaurants and 100 countries. The firm generates revenue primarily from retail sales at its company-owned restaurants, royalty fees and lease income from franchised stores, and from its Tim Horton’s supply chain operations. Formed in 2014 after 3G Capital’s acquisition of Tim Horton’s International, the Restaurant Brands portfolio now includes Burger King (19,250 units), Tim Horton’s (5,300 units), and Popeyes Louisiana Kitchen (3,700 units).

See Also Five stocks we like better than Restaurant Brands International 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Receive News & Ratings for Restaurant Brands International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Restaurant Brands International and related companies with MarketBeat.com's FREE daily email newsletter.

New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571.

Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"

On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik® (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged." As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."

Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313452

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

-

Leading German health insurer brings NiCE Cognigy AI agents and CXone together to support more than 5 million annual member interactions

HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced that AOK PLUS is now live on NiCE Cognigy and CXone, making it one of the first customers to bring AI agents and member service operations together on NiCE’s unified CX AI platform. The deployment unites AI-powered self-service, intelligent orchestration, workflows and employee expertise to support more than 5 million annual member interactions.

AOK PLUS began its AI transformation with NiCE Cognigy in 2025, introducing AI-powered voice self-service to identify member needs and direct inquiries to the appropriate teams. With CXone, AOK PLUS is extending that intelligence across its broader member service operation, connecting AI-powered interactions with 2,400 employees and 120 skills that intelligently route inquiries based on employee competencies. Together, NiCE Cognigy and CXone create one foundation for orchestrating automated and employee-assisted service from interaction to resolution.

The unified approach is already operating at significant scale. AOK PLUS is supporting more than 5 million annual member interactions on CXone and has achieved a call acceptance rate above 95%. The organization also migrated more than 1,400 telephone numbers with zero downtime. The implementation was delivered by NiCE in collaboration with long-standing Platinum partner CCT Solutions.

Trust and data sovereignty are central to AOK PLUS’s approach. The organization is among the first public health insurers in Germany to move member service operations to the cloud and the first insurer in Saxony and Thuringia to deploy AI-powered voice automation in a sovereign cloud environment. Deployed in NiCE’s EU Sovereign Cloud, CXone provides the security, governance and data sovereignty required to scale AI while meeting stringent German and European healthcare requirements.

“Our members are getting faster, more personalized support without ever losing the security and trust they expect,” said Sebastian Reichenbach, Project Lead Customer Experience & Contact Center, AOK PLUS. “That’s what happens when AI agents and our 2,400 employees work from the same platform, so no matter who or what responds, the experience feels seamless.”

“AOK PLUS is turning millions of member interactions into personalized, trusted experiences at scale, and that’s the real payoff of bringing AI agents and member service together on one platform,” said Darren Rushworth, President, NiCE International. “And they’re doing it without compromising the security and data sovereignty their members expect.”

About AOK PLUS

AOK PLUS – The Health Insurance Fund for Saxony and Thuringia is a federal agency operating within Germany's statutory health insurance system. Headquartered in Dresden, AOK PLUS serves more than 3.4 million members through more than 130 local branches across Saxony and Thuringia and employs approximately 7,000 people. For more information, visit www.aok.de.

About NiCE

NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE’s platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.

Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Rushworth are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

More News From NiCE

Back to Newsroom

In the latest trading session, Reddit Inc. (RDDT - Free Report) closed at $149.38, marking a -3.29% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.

Shares of the company have depreciated by 2.68% over the course of the past month, underperforming the Computer and Technology sector's gain of 0.12%, and the S&P 500's loss of 0.36%.

Analysts and investors alike will be keeping a close eye on the performance of Reddit Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.33, signifying a 66.25% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $886.87 million, indicating a 51.62% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.27 per share and revenue of $3.39 billion, indicating changes of +101.15% and +54.05%, respectively, compared to the previous year.

Investors might also notice recent changes to analyst estimates for Reddit Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.97% upward. At present, Reddit Inc. boasts a Zacks Rank of #3 (Hold).

In terms of valuation, Reddit Inc. is currently trading at a Forward P/E ratio of 29.3. For comparison, its industry has an average Forward P/E of 20.46, which means Reddit Inc. is trading at a premium to the group.

Also, we should mention that RDDT has a PEG ratio of 0.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Internet - Software stocks are, on average, holding a PEG ratio of 1.08 based on yesterday's closing prices.

The Internet - Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 35% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow RDDT in the coming trading sessions, be sure to utilize Zacks.com.

Shares of Allient Inc. (NASDAQ:ALNT – Get Free Report) have been given an average rating of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $84.00.

Several analysts have commented on the company. Jefferies Financial Group set a $80.00 target price on Allient in a research note on Tuesday, May 26th. Wall Street Zen upgraded Allient from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Zacks Research raised Allient from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. Macquarie Infrastructure set a $80.00 price objective on Allient in a research report on Tuesday, May 26th. Finally, JPMorgan Chase & Co. lifted their price objective on Allient from $95.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, August 7th.

Check Out Our Latest Stock Analysis on Allient

Insider Activity In other news, CEO Richard Warzala sold 70,000 shares of Allient stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $113.58, for a total value of $7,950,600.00. Following the completion of the sale, the chief executive officer directly owned 1,499,106 shares in the company, valued at $170,268,459.48. The trade was a 4.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 15.00% of the stock is currently owned by insiders. Institutional Inflows and Outflows Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Allient during the second quarter valued at approximately $721,000. California State Teachers Retirement System raised its stake in Allient by 12,285.6% during the 2nd quarter. California State Teachers Retirement System now owns 1,604,679 shares of the company’s stock valued at $165,170,000 after buying an additional 1,591,723 shares during the last quarter. Round Rock Advisors LLC lifted its holdings in shares of Allient by 8.2% during the 2nd quarter. Round Rock Advisors LLC now owns 24,086 shares of the company’s stock valued at $2,479,000 after buying an additional 1,822 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Allient during the 2nd quarter valued at $3,181,000. Finally, Navellier & Associates Inc. boosted its stake in shares of Allient by 158.7% in the 2nd quarter. Navellier & Associates Inc. now owns 17,975 shares of the company’s stock worth $1,850,000 after buying an additional 11,027 shares during the last quarter. Institutional investors own 61.57% of the company’s stock.

Allient Trading Up 1.1% Shares of NASDAQ ALNT opened at $95.63 on Friday. The firm’s 50 day moving average price is $94.16 and its 200-day moving average price is $80.36. Allient has a 52-week low of $41.75 and a 52-week high of $118.67. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.95 and a current ratio of 3.42. The company has a market cap of $1.63 billion, a PE ratio of 56.25 and a beta of 1.62.

Allient (NASDAQ:ALNT – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.19. Allient had a net margin of 4.98% and a return on equity of 13.55%. The company had revenue of $153.77 million during the quarter, compared to the consensus estimate of $145.68 million. On average, equities research analysts expect that Allient will post 2.73 EPS for the current fiscal year.

Allient Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Wednesday, September 2nd. Stockholders of record on Wednesday, August 19th were issued a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend was Wednesday, August 19th. Allient’s dividend payout ratio (DPR) is presently 9.41%.

Allient Company Profile (Get Free Report)

Allient Inc, together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives.

Featured Stories Five stocks we like better than Allient Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For

Receive News & Ratings for Allient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allient and related companies with MarketBeat.com's FREE daily email newsletter.

Hudson Pacific Properties (NYSE:HPP – Get Free Report) and COPT Defense Properties (NYSE:CDP – Get Free Report) are both real estate companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Insider & Institutional Ownership 97.6% of Hudson Pacific Properties shares are held by institutional investors. 2.5% of Hudson Pacific Properties shares are held by insiders. Comparatively, 1.7% of COPT Defense Properties shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings This is a breakdown of recent ratings and target prices for Hudson Pacific Properties and COPT Defense Properties, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hudson Pacific Properties 3 5 4 1 2.23 COPT Defense Properties 0 3 5 0 2.62 Hudson Pacific Properties presently has a consensus price target of $15.82, suggesting a potential upside of 30.39%. COPT Defense Properties has a consensus price target of $37.38, suggesting a potential upside of 5.49%. Given Hudson Pacific Properties’ higher probable upside, equities research analysts plainly believe Hudson Pacific Properties is more favorable than COPT Defense Properties. Earnings and Valuation This table compares Hudson Pacific Properties and COPT Defense Properties”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hudson Pacific Properties $831.10 million 0.79 -$561.69 million ($8.85) -1.37 COPT Defense Properties $784.18 million 5.12 $152.32 million $1.44 24.60 COPT Defense Properties has lower revenue, but higher earnings than Hudson Pacific Properties. Hudson Pacific Properties is trading at a lower price-to-earnings ratio than COPT Defense Properties, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk Hudson Pacific Properties has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, COPT Defense Properties has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability This table compares Hudson Pacific Properties and COPT Defense Properties’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Hudson Pacific Properties -70.04% -20.76% -7.73% COPT Defense Properties 20.94% 10.48% 3.64% Summary COPT Defense Properties beats Hudson Pacific Properties on 9 of the 15 factors compared between the two stocks.

(Get Free Report)

Hudson Pacific Properties (NYSE: HPP) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific's unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

About COPT Defense Properties (Get Free Report)

COPT Defense Properties is a real estate investment trust. It acquires, develops, manages, sells, and leases out office properties and data centers. The firm operates through the following segments: Defense/Information Technology Locations, Regional Office, Wholesale Data Center, and Other. The company was founded on January 22,1988 and is headquartered in Columbia, MD.

Receive News & Ratings for Hudson Pacific Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hudson Pacific Properties and related companies with MarketBeat.com's FREE daily email newsletter.

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects Signet Jewelers Ltd (NYSE:SIG) to report quarterly earnings of $1.74 per share on revenue of $1.53 billion before the opening bell. Signet shares gained 1.5% to $83.89 in after-hours trading. Mission Produce Inc (NASDAQ:AVO) posted better-than-expected third-quarter results. Mission Produce reported quarterly earnings of 18 cents per share, which beat the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $450.000 million, which beat the analyst consensus estimate of $367.475 million. Mission Produce shares gained 5.5% to $13.58 in the after-hours trading session. Analysts are expecting American Eagle Outfitters Inc (NYSE:AEO) to post quarterly earnings of 22 cents per share on revenue of $1.37 billion. The company will release earnings after the markets close. American Eagle shares fell 1% to close at $17.22 on Tuesday. Check out our premarket coverage here

Caseys’ General Stores Inc (NASDAQ:CASY) posted upbeat first-quarter results. The company posted quarterly earnings of $7.37 per share, beating market estimates of $6.72 per share. The company’s sales came in at $5.678 billion versus expectations of $5.568 billion. Casey’s shares dipped 8.3% to $672.50 in the after-hours trading session. Analysts expect Core & Main Inc (NYSE:CNM) to post quarterly earnings of 92 cents per share on revenue of $2.14 billion before the opening bell. Core & Main shares fell 0.2% to $43.98 in after-hours trading. Photo via Shutterstock

Trending

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

New 224G TIA and driver portfolio targets NPO and CPO architectures for AI clusters and hyperscale data centers

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, today introduced a family of 224G linear Transimpedance Amplifier (TIA) and driver solutions, designed to accelerate the deployment of Near-Packaged Optics (NPO) and Co-Packaged Optics (CPO) architectures for AI/ML clusters, hyperscale data centers and next-generation networking platforms.

As AI workloads continue to drive unprecedented demand for bandwidth and connectivity, traditional optical architectures face increasing challenges in power consumption, thermal management, signal integrity, and system density. By bringing high-performance optical interfaces closer to the switching and compute silicon, NPO and CPO architectures offer a path toward significantly higher bandwidth density and improved system-level efficiency.

“Near-packaged and co-packaged optics are entering their initial ramp in 2026, and the shift toward NPO and CPO architectures reflects a broader industry response to the power and scaling bottlenecks facing AI back-end networks,” said Sameh Boujelbene, vice president, data center switch and AI networks market research at Dell’Oro Group. “As hyperscalers move these architectures from trials to deployment, the underlying TIA and driver technology becomes a critical enabler of that transition.”

Designed for 224G Linear Optical Architectures

Semtech’s new products include the GN1838L and GN42T380, the industry’s first linear octal TIAs, and the GN42M380 linear octal Mach-Zehnder Modulator (MZM) driver, optimized for 1.6T, 3.2T, 6.4T, and 12.8T optical engines (OEs). The 224G TIA and driver portfolio optimizes for CEI-224G-Linear and Open CPX interfaces and linear architectures, with very strictly specified space and power dissipation requirements.

“AI infrastructure is fundamentally changing the requirements for optical connectivity,” said Amit Thakar, vice president, signal integrity product marketing at Semtech. “At 224G per lane, designers need more than bandwidth. They need signal integrity, power efficiency, flexibility, and system-level visibility. Our TIAs and driver solutions are purpose-built to give NPO and CPO developers the building blocks to scale optical I/O while addressing the power and density challenges of next-generation AI systems.”

Enabling NPO and CPO at Scale

The GN1838L TIA offers 500µm channel pitch and the GN42T380 offers a 375µm channel pitch, giving customers flexibility in OE design choices. These TIAs can be used in side-by-side configuration with the photonics integrated circuit (PIC) or placed directly on top of the PIC, giving customers maximum flexibility. Both TIAs include an Automatic Gain Control (AGC) stage and output driver featuring programmable Continuous Time Linear Equalization (CTLE) and support both Manual and Automatic Gain Control (MGC and AGC) modes. The bandwidth is optimized to achieve low peaking, low input referred noise (IRN), and good group delay with minimal distortion. The devices offer several programmable performance optimization features, including output equalization, and are designed to interface with a wide variety of optical input signals, while optimizing performance at the switch or ASIC input.

The GN42M380 driver offers 375µm channel pitch and supports a variety of modulators, including Silicon Photonics (SiPho), Indium Phosphide Mach-Zehnder Modulator (InP MZM) and Thin-Film Lithium Niobate (TFLN). The GN42M380 delivers low group delay and minimal Total Harmonic Distortion (THD), ensuring superior driver performance. Programmable Continuous Time Linear Equalization (CTLE) is included to help compensate for intersymbol interference (ISI) due to the input signal transmission path. It also offers flexible biasing, making it compatible with MZMs from various vendors. The driver output swing is configurable, and on-chip equalization enables precise tuning of electrical and optical performance.

The TIA and driver family integrates several diagnostics and performance tuning features that can be accessed through device pads and the I²C interface.

Availability

Contact Semtech for the availability of the GN1838L, GN42T380 and GN42M380 product family.

Customers and partners are invited to visit Semtech at Booth #11C52 during CIOE 2026, Sept. 9-11, in Shenzhen, China, to learn more about the portfolio and meet with Semtech’s technical experts.

Learn more at http://www.semtech.com/optical.

About Semtech

Semtech Corporation (Nasdaq: SMTC) is a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected IoT devices worldwide. Our global teams are committed to empowering solution architects and application developers to develop breakthrough products for the infrastructure, industrial and consumer markets. To learn more about Semtech technology, visit us at Semtech.com or follow us on LinkedIn or X.

Semtech and the Semtech logo are registered trademarks or service marks of Semtech Corporation or its subsidiaries. All other trademarks, service marks and trade names mentioned in this press release are the property of their respective owners.

SMTC-P

More News From Semtech Corporation

Back to Newsroom

Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, today introduced a family of 224G linear Transimpedance Amplifier (TIA) and driver solutions, designed to accelerate the deployment of Near-Packaged Optics (NPO) and Co-Packaged Optics (CPO) architectures for AI/ML clusters, hyperscale data centers and next-generation networking platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908403246/en/

Semtech's new 224G linear TIA and driver portfolio — the GN1838L, GN42T380 and GN42M380 — is designed to accelerate NPO and CPO architectures for AI/ML clusters and hyperscale data centers.

As AI workloads continue to drive unprecedented demand for bandwidth and connectivity, traditional optical architectures face increasing challenges in power consumption, thermal management, signal integrity, and system density. By bringing high-performance optical interfaces closer to the switching and compute silicon, NPO and CPO architectures offer a path toward significantly higher bandwidth density and improved system-level efficiency.

“Near-packaged and co-packaged optics are entering their initial ramp in 2026, and the shift toward NPO and CPO architectures reflects a broader industry response to the power and scaling bottlenecks facing AI back-end networks,” said Sameh Boujelbene, vice president, data center switch and AI networks market research at Dell’Oro Group. “As hyperscalers move these architectures from trials to deployment, the underlying TIA and driver technology becomes a critical enabler of that transition.”

Designed for 224G Linear Optical Architectures

Semtech’s new products include the GN1838L and GN42T380, the industry’s first linear octal TIAs, and the GN42M380 linear octal Mach-Zehnder Modulator (MZM) driver, optimized for 1.6T, 3.2T, 6.4T, and 12.8T optical engines (OEs). The 224G TIA and driver portfolio optimizes for CEI-224G-Linear and Open CPX interfaces and linear architectures, with very strictly specified space and power dissipation requirements.

“AI infrastructure is fundamentally changing the requirements for optical connectivity,” said Amit Thakar, vice president, signal integrity product marketing at Semtech. “At 224G per lane, designers need more than bandwidth. They need signal integrity, power efficiency, flexibility, and system-level visibility. Our TIAs and driver solutions are purpose-built to give NPO and CPO developers the building blocks to scale optical I/O while addressing the power and density challenges of next-generation AI systems.”

Enabling NPO and CPO at Scale

The GN1838L TIA offers 500µm channel pitch and the GN42T380 offers a 375µm channel pitch, giving customers flexibility in OE design choices. These TIAs can be used in side-by-side configuration with the photonics integrated circuit (PIC) or placed directly on top of the PIC, giving customers maximum flexibility. Both TIAs include an Automatic Gain Control (AGC) stage and output driver featuring programmable Continuous Time Linear Equalization (CTLE) and support both Manual and Automatic Gain Control (MGC and AGC) modes. The bandwidth is optimized to achieve low peaking, low input referred noise (IRN), and good group delay with minimal distortion. The devices offer several programmable performance optimization features, including output equalization, and are designed to interface with a wide variety of optical input signals, while optimizing performance at the switch or ASIC input.

The GN42M380 driver offers 375µm channel pitch and supports a variety of modulators, including Silicon Photonics (SiPho), Indium Phosphide Mach-Zehnder Modulator (InP MZM) and Thin-Film Lithium Niobate (TFLN). The GN42M380 delivers low group delay and minimal Total Harmonic Distortion (THD), ensuring superior driver performance. Programmable Continuous Time Linear Equalization (CTLE) is included to help compensate for intersymbol interference (ISI) due to the input signal transmission path. It also offers flexible biasing, making it compatible with MZMs from various vendors. The driver output swing is configurable, and on-chip equalization enables precise tuning of electrical and optical performance.

The TIA and driver family integrates several diagnostics and performance tuning features that can be accessed through device pads and the I²C interface.

Availability

Contact Semtech for the availability of the GN1838L, GN42T380 and GN42M380 product family.

Customers and partners are invited to visit Semtech at Booth #11C52 during CIOE 2026, Sept. 9-11, in Shenzhen, China, to learn more about the portfolio and meet with Semtech’s technical experts.

Learn more at http://www.semtech.com/optical.

About Semtech

Semtech Corporation (Nasdaq: SMTC) is a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected IoT devices worldwide. Our global teams are committed to empowering solution architects and application developers to develop breakthrough products for the infrastructure, industrial and consumer markets. To learn more about Semtech technology, visit us at Semtech.com or follow us on LinkedIn or X.

Semtech and the Semtech logo are registered trademarks or service marks of Semtech Corporation or its subsidiaries. All other trademarks, service marks and trade names mentioned in this press release are the property of their respective owners.

SMTC-P

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908403246/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

PALO ALTO, Calif.--(BUSINESS WIRE)--Rubrik (NYSE: RBRK), the Security and AI Operations Company, today announced Rubrik Apache Iceberg Protection, the company's enterprise data protection capability for Apache Iceberg on Amazon Web Services (AWS). The new solution expands Rubrik's cloud data security and AI governance portfolio on AWS. It provides customers running Apache Iceberg the ability to recover complete, queryable tables following a cyber incident, so they respond and recover with great.